AbCellera Biologics (NASDAQ:ABCL) used its full-year 2025 business update call to emphasize that it has completed its ...
The prices importers can get from selling rights to potential government refunds have surged in the wake of the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results